NAUT trades 57.0% below Wall Street's consensus target of $3.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NAUT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Nautilus Biotechnolgy, Inc. (NAUT) has a Wall Street consensus price target of $3.50, based on estimates from 5 covering analysts. With the stock currently trading at $2.23, this represents a potential upside of +57.0%. The company has a market capitalization of $284M.
Analyst price targets range from a low of $3.50 to a high of $3.50, representing a 0% spread in expectations. The median target of $3.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NAUT trades at a trailing P/E of -4.8x. Analysts expect EPS to grow -5.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CDNACareDx, Inc | $4.1B | $78.56 | $75.25 | -4.2% | Buy | 44.1x | 14 |
 SEERSeer, Inc. | $90M | $1.63 | $4.00 | +145.4% | Hold | — | 4 |
 QBTSD-Wave Quantum Inc. | $3.9B | $10.68 | $36.14 | +238.4% | Buy | — | 13 |
 ILMNIllumina, Inc. | $32.2B | $213.13 | $252.73 | +18.6% | Buy | 39.4x | 50 |
 PACBPacific Biosciences of California, Inc. | $702M | $2.26 | $1.93 | -14.4% | Buy | — | 18 |
 BFLYButterfly Network, Inc. | $1.7B | $6.37 | $11.67 | +83.2% | Buy | — | 7 |
 TWSTTwist Bioscience Corporation | $7.5B | $120.79 | $153.70 | +27.2% | Buy | — | 15 |
 BEAMBeam Therapeutics Inc. | $2.7B | $26.41 | $66.00 | +149.9% | Buy | — | 28 |
 SRPTSarepta Therapeutics, Inc. | $1.9B | $17.82 | $21.00 | +17.8% | Buy | 5.8x | 55 |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
Quick answers to the most common questions about buying NAUT stock.
The consensus Wall Street price target for NAUT is $3.5, representing 57.0% upside from the current price of $2.23. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NAUT has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $3.5 implies 57.0% upside from current levels.
NAUT's current price is $2.23 with a consensus target of $3.5 (57.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $3.5 for NAUT, while the most conservative target is $3.5. The consensus of $3.5 represents the median expectation. These targets typically reflect 12-month expectations.
NAUT is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NAUT stock forecast based on 5 Wall Street analysts shows a consensus price target of $3.5, with estimates ranging from $3.5 (bear case) to $3.5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NAUT, with a "Buy" consensus rating and $3.5 price target (57.0% upside). 3 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NAUT analyst price targets range from $3.5 to $3.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.